461418-01-9

Upstream product

• 5748-43-6 4-(2-methylphenyl)benzoic acid 
• 84348-37-8 N-tert-butoxycarbonyl-4-oxo-L-proline 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 461418-07-5 1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate 
• 364077-88-3 (4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-L-proline 
• 461418-05-3 (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline 
• 616-42-2 dimethylsulfite 
• 77-78-1 dimethyl sulfate 
• 16419-60-6 2-Methylphenylboronic acid 

Downstream Products

• 461418-05-3 (4Z/E)-4-methoxyimino-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]-L-proline 

Relevant academic research and scientific papers

OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE

The disclosure provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives of formula (I), among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compos

BIOMARKERS FOR OXYTOCIN RECEPTOR ANTAGONIST THERAPY

The disclosure provides compositions and methods for determining the propensity of a subject (e.g., a female human subject) undergoing embryo transfer therapy to benefit from administration of an oxytocin receptor antagonist, as well as for treating such

OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE

The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compositions and metho

Differential effects of oxytocin receptor antagonists, atosiban and nolasiban, on oxytocin receptor-mediated signaling in human amnion and myometrium

One of the most established roles of oxytocin (OT) is in inducing uterine contractions and labor. Apart from inducing contractions, our recent studies showed that OT can also activate proinflammatory pathways in both human myometrial and amnion cells, whi

CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity,

PYRROLIDINE DERIVATIVES AS OXYTOCIN / VASOPRESSIN V1a RECEPTORS ANTAGONISTS

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1- [(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or v

ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES

The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one- O-methyloxime, and/or an active metabolite thereof, and the use of said formula

PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methy19243-yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or

ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES

The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulat

PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS

The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1-C6-alkyl, for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea.